microdosing glp 1 agonists THE GLP-1 PROGRAM Microdosing GLP-1s: How (and Why)

LY2189265, a longacting glucagonlike peptide1 analogue, showed a dosedependent effect on insulin secretion in healthy subjects

FDA has approved dipeptidyl peptidase-4 (DPP-IV) resistant long-acting GLP-1s as injectable drugs for treating patients with type 2 diabetes

Special Considerations and Interactions FDA-Approved Oral Semaglutide May Not Work Well If You Have: Gastrointestinal disorders affecting absorption Liver conditions Difficulty maintaining strict morning medication routines Compounded ODT Formulations Considerations: Not FDA-approved

Indeed, it is important to start low and go slow : the lowest dose of medication should be used to start, and HCPs should ensure that patients follow their instructions closely

What if you stop

Toxicon 2012;59:46471.ArticlePubMed 38